Compare Merck & Co., Inc. (MRK) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Roblox Corp — how do they compare? Merck & Co., Inc. trades at $133.42 (market cap $321.77B), while Roblox Corp trades at $35.6 (market cap $25.87B). The key difference: Merck & Co., Inc. is far larger — about 12.4× Roblox Corp's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| MRK | RBLX | |
|---|---|---|
Market Cap | $321.77B | $25.87B |
Sector | Health | Media |
52-Week High | $131.84 | $141.56 |
52-Week Low | $77.60 | $35.60 |
Enterprise Value | $368.53B | $24.70B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
RBLX trades at $35.76, down 3.48% in the last session, with a bearish technical outlook from moving averages. The company reported revenue growth to $4.89 billion in 2025 but remains unprofitable, with a net loss of $1.07 billion. Analyst consensus is mixed, with a $45.67 price target, while recent news highlights multiple class-action lawsuits filed against the company.
The outlook is clouded by persistent losses and legal challenges, though revenue growth and strong operating cash flow of $1.80 billion offer some fundamental support. Risks include profitability challenges and litigation, but the stock may appeal to growth-oriented investors if execution improves and losses narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
